NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

TB & Outbreaks Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB & Outbreaks Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Tuberculosis



New findings reported from A. Lacoma and co-authors describe advances in tuberculosis



December 23rd, 2008

"The purpose of this study was to evaluate the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to rifampin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis clinical strains and directly in clinical samples. A total of 62 clinical strains characterized with the Bactec 460TB system were included," scientists in Barcelona, Spain report.

"For the INH-resistant strains, the MIC was measured and sequencing was performed. Sixty-five clinical samples from 28 patients (39 smear-positive samples and 26 smear-negative samples) were also tested directly. The corresponding isolates of the clinical specimens were studied...


Source: TB & Outbreaks Week (2008-12-23)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login